Pulmonx Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.6%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$90.5Mnext fiscal year
FY EPS (est.)
-$1.04next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 28 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Worldwide Revenue Quarterly20.6MTarget: 90000000 to 92000000
Gross Margin Quarterly78.0%
Operating Expenses Quarterly29MTarget: 113000000 to 115000000
Watch Items
- China Registration RenewalTrigger: Resumption of direct sales into ChinaAction: Monitor regulatory updates from China's NMPA regarding the renewal of the Zephyr Valve registration certificate, which caused a lack of sales in Q1 2026.
- CONVERT II Pivotal Trial EnrollmentTrigger: Complete enrollment in 2027Action: Track patient enrollment velocity for the AeriSeal System trial, which is expected to expand the global addressable market by approximately 20%.
- U.S. Commercial Strategy ExecutionTrigger: Return to year-over-year growth in the back half of 2026Action: Evaluate the productivity of the refocused U.S. sales organization and sequential quarterly improvements in domestic procedure volumes.
Research as of 19 Jun 2026